KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables - Other (2016 - 2025)

Sarepta Therapeutics has reported Receivables - Other over the past 15 years, most recently at $104.1 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 200.87% year-over-year to $104.1 million; the TTM value through Dec 2025 reached $104.1 million, up 200.87%, while the annual FY2025 figure was $104.1 million, 200.87% up from the prior year.
  • Receivables - Other for Q4 2025 was $104.1 million at Sarepta Therapeutics, down from $128.7 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $128.7 million in Q3 2025 and troughed at $8000.0 in Q4 2021.
  • A 5-year average of $41.9 million and a median of $30.0 million in 2023 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: crashed 99.98% in 2021 and later surged 522400.0% in 2022.
  • Year by year, Receivables - Other stood at $8000.0 in 2021, then surged by 522400.0% to $41.8 million in 2022, then dropped by 28.71% to $29.8 million in 2023, then rose by 16.11% to $34.6 million in 2024, then soared by 200.87% to $104.1 million in 2025.
  • Business Quant data shows Receivables - Other for SRPT at $104.1 million in Q4 2025, $128.7 million in Q3 2025, and $73.3 million in Q2 2025.